MedTrace Logo

Genotype-guided Supportive Care in Symptom Treatment of Cancer Patients

NCT03924557 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2023-01-27

No results posted yet for this study

Summary

Cancer patients often require administration of multiple supportive care pharmacotherapies while receiving chemotherapy regardless the type of cancer. Supportive care therapies are commonly prescribed to nearly all cancer patients and could include antiemetics (ondansetron), pain management (opiates), GI protection (PPIs), antidepressants (select SSRIs), anticoagulation (warfarin) and antifungal prophylaxis (voriconazole). These are all are associated with known pharmacogenetic interactions, which in some cases render the drugs ineffective or toxic. This could result in negative impacts on quality of life in patients who are already undergoing complicated and costly anticancer regimens. Pharmacogenetic-guided therapy based on an individual patient's genetic profile could potentially target symptoms for which an individual is uniquely susceptible, guiding use of medications that are most likely to be effective, thereby reducing unnecessary physical complications and financial strain. It is hypothesized that patients in the genotype intervention arm will report lower scores for overall symptom distress as compared to patients in the delayed genotype intervention arm following initiation of chemotherapy.

Conditions

  • Chemotherapy
  • Supportive Care
  • Genotyping

Interventions

DIAGNOSTIC_TEST

Genotype-guided Supportive Care

In this arm, supportive care will be administered based on the results of the genotype test.

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Rhonda Cooper-DeHoff, Pharm D, MS · University of Florida

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-09
Primary Completion
2021-04-13
Completion
2021-04-13

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03924557 on ClinicalTrials.gov